Star Equity Holdings, Inc. (STRR)
USD 2.36
(-2.88%)
USD 2.36
(-2.88%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.6 Million USD | -78.81% |
| 2022 | 17.03 Million USD | -2.23% |
| 2021 | 17.42 Million USD | -33.53% |
| 2020 | 26.2 Million USD | 0.75% |
| 2019 | 26.01 Million USD | 173.82% |
| 2018 | 9.5 Million USD | -51.28% |
| 2017 | 19.5 Million USD | -9.0% |
| 2016 | 21.42 Million USD | 2859.67% |
| 2015 | 724 Thousand USD | 108.05% |
| 2014 | 348 Thousand USD | 100.0% |
| 2013 | 174 Thousand USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | -100.0% |
| 2007 | 213 Thousand USD | -42.12% |
| 2006 | 368 Thousand USD | -67.55% |
| 2005 | 1.13 Million USD | -71.52% |
| 2004 | 3.98 Million USD | -75.78% |
| 2003 | 16.44 Million USD | 18.01% |
| 2002 | 13.93 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 3.39 Million USD | -5.82% |
| 2024 Q2 | 15.69 Million USD | 361.61% |
| 2023 Q4 | 3.6 Million USD | 61.19% |
| 2023 FY | 3.6 Million USD | -78.81% |
| 2023 Q1 | 13.16 Million USD | -22.73% |
| 2023 Q3 | 2.23 Million USD | 23.77% |
| 2023 Q2 | 1.8 Million USD | -86.26% |
| 2022 Q4 | 17.03 Million USD | -3.64% |
| 2022 Q3 | 17.67 Million USD | -0.13% |
| 2022 Q1 | 19.95 Million USD | 14.52% |
| 2022 FY | 17.03 Million USD | -2.23% |
| 2022 Q2 | 17.7 Million USD | -11.28% |
| 2021 FY | 17.42 Million USD | -33.53% |
| 2021 Q2 | 16.31 Million USD | -17.29% |
| 2021 Q3 | 17.76 Million USD | 8.93% |
| 2021 Q4 | 17.42 Million USD | -1.96% |
| 2021 Q1 | 19.72 Million USD | -24.75% |
| 2020 Q1 | 25.39 Million USD | -2.36% |
| 2020 Q4 | 26.2 Million USD | 1.28% |
| 2020 Q3 | 25.87 Million USD | -9.48% |
| 2020 Q2 | 28.58 Million USD | 12.55% |
| 2020 FY | 26.2 Million USD | 0.75% |
| 2019 FY | 26.01 Million USD | 173.82% |
| 2019 Q1 | 16.33 Million USD | 71.92% |
| 2019 Q2 | 19.41 Million USD | 18.88% |
| 2019 Q3 | 26.35 Million USD | 35.72% |
| 2019 Q4 | 26.01 Million USD | -1.28% |
| 2018 Q3 | 13.59 Million USD | 8.74% |
| 2018 Q1 | 13 Million USD | -33.33% |
| 2018 Q4 | 9.5 Million USD | -30.11% |
| 2018 Q2 | 12.5 Million USD | -3.85% |
| 2018 FY | 9.5 Million USD | -51.28% |
| 2017 Q3 | 18.5 Million USD | 5.85% |
| 2017 FY | 19.5 Million USD | -9.0% |
| 2017 Q2 | 17.47 Million USD | -13.26% |
| 2017 Q4 | 19.5 Million USD | 5.41% |
| 2017 Q1 | 20.15 Million USD | -5.96% |
| 2016 Q3 | 22.69 Million USD | -7.72% |
| 2016 FY | 21.42 Million USD | 2859.67% |
| 2016 Q4 | 21.42 Million USD | -5.6% |
| 2016 Q2 | 24.59 Million USD | -21.19% |
| 2016 Q1 | 31.21 Million USD | 4211.05% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | 724 Thousand USD | 108.05% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q4 | 724 Thousand USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | 348 Thousand USD | 100.0% |
| 2014 Q4 | 348 Thousand USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q1 | - USD | -100.0% |
| 2013 Q1 | - USD | -100.0% |
| 2013 FY | 174 Thousand USD | 0.0% |
| 2013 Q4 | 174 Thousand USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | 41 Thousand USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q1 | 217 Thousand USD | 1.88% |
| 2008 Q4 | - USD | -100.0% |
| 2008 Q3 | 164 Thousand USD | 3.8% |
| 2008 FY | - USD | -100.0% |
| 2008 Q2 | 158 Thousand USD | -27.19% |
| 2007 FY | 213 Thousand USD | -42.12% |
| 2007 Q4 | 213 Thousand USD | 3.4% |
| 2007 Q3 | 206 Thousand USD | -22.85% |
| 2007 Q2 | 267 Thousand USD | -20.3% |
| 2007 Q1 | 335 Thousand USD | -8.97% |
| 2006 FY | 368 Thousand USD | -67.55% |
| 2006 Q2 | 643 Thousand USD | -27.83% |
| 2006 Q3 | 481 Thousand USD | -25.19% |
| 2006 Q1 | 891 Thousand USD | -21.43% |
| 2006 Q4 | 368 Thousand USD | -23.49% |
| 2005 Q2 | 1.6 Million USD | -10.95% |
| 2005 FY | 1.13 Million USD | -71.52% |
| 2005 Q1 | 1.79 Million USD | -54.82% |
| 2005 Q3 | 1.37 Million USD | -14.48% |
| 2005 Q4 | 1.13 Million USD | -17.23% |
| 2004 Q1 | 15.84 Million USD | 0.0% |
| 2004 Q2 | 5.76 Million USD | -63.59% |
| 2004 Q3 | 5.06 Million USD | -12.16% |
| 2004 FY | 3.98 Million USD | -75.78% |
| 2004 Q4 | 3.98 Million USD | -21.41% |
| 2003 FY | 16.44 Million USD | 18.01% |
| 2002 FY | 13.93 Million USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bionano Genomics, Inc. | 87.94 Million USD | 95.896% |
| Prenetics Global Limited | 2.36 Million USD | -52.318% |
| CareDx, Inc | 34.22 Million USD | 89.454% |
| Exact Sciences Corporation | 2.55 Billion USD | 99.859% |
| Exagen Inc. | 23.72 Million USD | 84.786% |
| Inotiv, Inc. | 417.64 Million USD | 99.136% |
| Guardant Health, Inc. | 1.35 Billion USD | 99.733% |
| Biodesix, Inc. | 60.69 Million USD | 94.053% |
| BioNexus Gene Lab Corp. | 133.39 Thousand USD | -2605.499% |
| Precipio, Inc. | 1.11 Million USD | -223.387% |
| iSpecimen Inc. | 196.24 Thousand USD | -1739.037% |
| Natera, Inc. | 441.99 Million USD | 99.183% |
| Aspira Women's Health Inc. | 2.26 Million USD | -59.267% |
| Standard BioTools Inc. | 98.21 Million USD | 96.325% |
| 23andMe Holding Co. | 76.51 Million USD | 95.283% |
| Castle Biosciences, Inc. | 15.31 Million USD | 76.427% |
| Personalis, Inc. | 48.96 Million USD | 92.629% |
| Aclaris Therapeutics, Inc. | 426 Thousand USD | -747.183% |
| Applied DNA Sciences, Inc. | 1.23 Million USD | -191.575% |
| OpGen, Inc. | 13.04 Million USD | 72.331% |
| T2 Biosystems, Inc. | 49.49 Million USD | 92.709% |
| Myriad Genetics, Inc. | 145 Million USD | 97.511% |
| ICON Public Limited Company | 3.93 Billion USD | 99.908% |
| NeoGenomics, Inc. | 611.67 Million USD | 99.41% |
| Star Equity Holdings, Inc. | 3.6 Million USD | 0.0% |
| IDEXX Laboratories, Inc. | 947.88 Million USD | 99.619% |
| RadNet, Inc. | 1.49 Billion USD | 99.758% |
| MDxHealth SA | 41.26 Million USD | 91.254% |
| Psychemedics Corporation | 2.29 Million USD | -57.05% |
| Illumina, Inc. | 2.26 Billion USD | 99.84% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 94.06 Million USD | 96.163% |
| DarioHealth Corp. | 29.54 Million USD | 87.783% |
| Fulgent Genetics, Inc. | 14.9 Million USD | 75.79% |
| Sera Prognostics, Inc. | 1.85 Million USD | -94.241% |
| ENDRA Life Sciences Inc. | 394.4 Thousand USD | -815.054% |
| OPKO Health, Inc. | 326.56 Million USD | 98.895% |
| Medpace Holdings, Inc. | 142.12 Million USD | 97.461% |
| Neogen Corporation | 906.23 Million USD | 99.602% |
| Intelligent Bio Solutions Inc. | 871.44 Thousand USD | -314.142% |
| Prenetics Global Limited | 2.36 Million USD | -52.318% |
| Mainz Biomed B.V. | 7.42 Million USD | 51.366% |
| bioAffinity Technologies, Inc. | 1.57 Million USD | -128.615% |
| Trinity Biotech plc | 67.42 Million USD | 94.648% |
| Neuronetics, Inc. | 62.47 Million USD | 94.223% |
| Sotera Health Company | 2.32 Billion USD | 99.845% |
| bioAffinity Technologies, Inc. | 1.57 Million USD | -128.615% |